People that are infected with HIV appear to be especially susceptible to the adverse effects
of cigarette smoking. The purpose of this study is to determine if quitting smoking by using
a specialized smoking cessation treatment can prevent one from developing accelerated lung
damage, particularly emphysema.
HIV-infected smokers are at increased risk for life-threatening diseases, such as pneumonia.
To date, very little is known about the tobacco consumption characteristics of this at-risk
population of smokers, but it has been well documented that they are at high risk for
smoking-related co-morbidities. In addition, few effective cessation strategies have been
described in HIV-infected populations. A specialized smoking cessation that combines
recommendations from an existing scientifically-valid clinical guideline with Motivational
Interviewing a new pharmacotherapeutic agent, may be an effective mechanism to apply to this
vulnerable population of smokers. This initial, efficacy investigation has the potential to
guide future treatment and research pertaining to tobacco cessation, respiratory illness and
1. 18 years of age and older;
2. diagnosis of HIV;
3. self-reported smoking on a daily basis;
4. provide informed written consent
1. persons with active psychosis or impaired mental status as judged by the clinic staff
and confirmed with a Mini-Mental Status Exam)
2. unable to understand spoken English
3. age less than 18 years.
4. pregnant women